본문 바로가기

전체 글

 (819)
Progressive Supranuclear Palsy Market According to DelveInsight, the market size of Progressive Supranuclear Palsy in 7MM was found to be USD 10.54 Million in 2017 and is expected to increase during the study period (2017-2030). In 2017, the total prevalent cases of Progressive Supranuclear Palsy were found to be 98,498 in seven major markets. The key players in Progressive Supranuclear Palsy market include AlzProtect, UCB Biopharma..
Progressive Supranuclear Palsy Market According to DelveInsight, the market size of Progressive Supranuclear Palsy in 7MM was found to be USD 10.54 Million in 2017 and is expected to increase during the study period (2017-2030). In 2017, the total prevalent cases of Progressive Supranuclear Palsy were found to be 98,498 in seven major markets. The key players in Progressive Supranuclear Palsy market include AlzProtect, UCB Biopharma..
Familial Chylomicronemia Syndrome Market The total prevalent population of Familial Chylomicronemia Syndrome (FCS) in the 7MM was found to be 5,801 in 2017. The therapeutic market of Familial Chylomicronemia Syndrome in seven major markets was found to be USD 1.0 Million in 2017 which is expected to increase during the study period (2017–2030). The key players in the Familial Chylomicronemia Syndrome Market include Akcea Therapeutics, ..
Duchenne Muscular Dystrophy Market The Duchenne Muscular Dystrophy Market Size (DMD Market) in the 7MM was found to be USD 266.06 Million in 2017, during the study period (2017-2030). Duchenne Muscular Dystrophy (DMD), approximately affects 1 in 3,500 male births globally. Moreover, Duchenne Muscular Dystrophy prevalence in the 7MM (The US, EU5, and Japan) was found to be approximately 31,386 in 2017 with the diagnosed prevalence..
Acute Kidney Injury Market As per DelveInsight Business Research LLP, the Acute Kidney Injury Market size in the 7 MM was observed to be USD 4,082.95 Million in 2017. The United States accounted for the maximum Acute Kidney Injury cases among 7MM countries with an incidence of 895,078 in 2017. On the other hand, Japan accounted for the least share of Acute Kidney Injury Incidence. Emerging therapies in the Acute kidney in..
Recent pharma happenings Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising. Thermo Fisher, WuXi and Mayo Clinic to develop COVID-19 antibody test Thermo Fisher Scientific is developing its COVID-19 antibody test through an ongoing, three-way pa..
LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035 According to DelveInsight, the LAG-3-Next Generation Immunotherapy market is expected to generate USD 3,421 Million in the year 2035 with a significant CAGR in the forecast period. NSCLC will occupy the major market share that is 98.81% by 2035. Launch of potential upcoming therapies, the addition of personalised drug therapies with combination therapies for efficacy enhancement, increased fundi..
TIM-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035 TIM-3 is a co-inhibitory receptor that is expressed on IFN-γ-producing T cells, FoxP3+ Treg cells and innate immune cells (macrophages and dendritic cells) where it has been shown to suppress their responses upon interaction with their ligand(s). TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that in vivo blockade of TIM-3 with other check-..

티스토리툴바